ADC Therapeutics Reports Preliminary Financials and Clinical Updates
ADC Therapeutics SA (NYSE: ADCT) has released preliminary unaudited financial results for the fourth quarter and full year of 2025. The company anticipates a net product revenue of approximately $22 million for Q4 and $73 million for the full year. Additionally, the company reported cash and cash equivalents of about $261 million as of December 31, 2025, suggesting a strong cash runway extending into 2028.
Financial Overview
For the full year 2025, ADC Therapeutics reported net product revenue of approximately $73 million, up from $69.3 million in 2024. The fourth quarter revenue is expected to reflect a significant improvement, rising from $16.4 million in Q4 2024, influenced by variations in customer ordering.
The underlying demand for ZYNLONTA, ADC Therapeutics' flagship product aimed at treating diffuse large B-cell lymphoma (DLBCL), has remained stable year-over-year. The cash reserves indicate that the company is well-positioned for ongoing operational activities through at least 2028.
Clinical Development Updates
Ameet Mallik, CEO of ADC Therapeutics, emphasized the progress made during 2025 in advancing the clinical program for ZYNLONTA. “We look forward to multiple clinical catalysts in 2026, including the full results from our LOTIS-5 and LOTIS-7 trials,” Mallik stated. The company anticipates achieving key milestones such as the completion of enrollment in the LOTIS-7 trial within the first half of 2026 and topline data from the LOTIS-5 trial in the second quarter of 2026.
- LOTIS-7 Trial: Updated data show an 89.8% best overall response rate and a 77.6% complete response rate from the study of ZYNLONTA combined with the bispecific antibody glofitamab (COLUMVI®).
- LOTIS-5 Results: Topline data is expected by the end of Q2 2026, with plans for FDA submission pending positive results.
- Investigator-Initiated Trials: Current trials for ZYNLONTA in treating indolent lymphomas have shown promising outcomes, with potential publication planned for late 2026.
Looking Ahead: Upcoming Catalysts
ADC Therapeutics is committed to expanding its product offerings and enhancing its market position. Key anticipated catalysts include:
- Completion of LOTIS-7 enrollment by mid-2026.
- Anticipation of LOTIS-5 topline data in Q2 2026.
- Potential compendia inclusions in the first half of 2027, with regulatory approvals for LOTIS-5 expected to follow.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a pioneer in antibody drug conjugates (ADCs), focusing on innovative treatments for challenging cancers. ZYNLONTA has received accelerated approval from the FDA for relapsed or refractory DLBCL and is currently in further development stages with a focus on enhancing patient outcomes.
Headquartered in Lausanne, Switzerland, with operations in London and New Jersey, ADC Therapeutics is dedicated to advancing ADC technology, from clinical trials to manufacturing and commercialization.
Forward-Looking Statements
This press release contains forward-looking statements related to ADC Therapeutics' future financial and clinical performance. Although the company aims to achieve its outlined goals, such statements are subject to uncertainties and risks that could result in actual outcomes differing significantly from expectations.